GUMC LogoThis news addresses the issue of breast cancer. A new study claims that a new drug cocktail could be the proper combination to combat breast cancer following the resistance to usual therapy. Particulars of this new study behind this approach propose that it could be feasible to re-sensitize tumors, thereby enabling treatments to function again.

This study apparently includes post-menopausal women whose advanced breast cancers are said to be increased by estrogen, frequently known as estrogen-receptor or progesterone-receptor positive cancers. The typical treatment is claimed to be anti-hormonal medicines like aromatase inhibitors (AIs), which is believed to decrease the quantity of estrogen in the body.

As time passes, nevertheless, the cancer could find a method to flourish devoid of the estrogen. The treatment approach under examination to apparently combat this resistance is to merge an aromatase inhibitor along with sorafenib, claimed to be an oral medication FDA-approved to treat liver and kidney cancers.

Claudine Isaacs, MD, clinical director of breast cancer program at Georgetown Lombardi Comprehensive Cancer Center and presenting author of the study, commented, “We believe the sorafenib might disrupt the machinery created by the tumor to grow without the estrogen. After the machinery is destroyed, the aromotase inhibitor can do its work again. We’re already seeing some encouraging responses to this approach.”

The multi-center, phase II study included around 35 post-menopausal women, who were suffering from metastatic breast cancer resistant to aromotase inhibitors. The women apparently carried on taking an aromotase inhibitor for the study, although sorafenib was also taken by them. This study is alleged to exhibit a clinical profit rate in around 20 percent of the women. By clinical benefit, one means that the patient appears to have absolute or incomplete reaction and also incorporates those who seemed to have the stable disease for around 6 months.

Isaacs mentioned that is result proposes that sorafenib is apparently acting to undo resistance to AIs as this kind of reaction could not have been anticipated with either sorafenib alone or with continuing the AI.

Issac remarked, “To manage breast cancer long term, it’s apparent that we may need to continually switch drugs to keep up with how a cancer evolves and evades each approach.”

Isaacs is of the opinion that the side-effects appeared to be general but most were mild or were controlled by decreasing the dose. These side effects are namely redness and irritation of the palms and soles, skin rash, fatigue, nausea/vomiting and diarrhea. Severe hypertension is said to have taken place in around 11 percent of the patients. Isaacs believed that the factor was apparently more effortlessly regulated if blood pressure was brought under good control before the patients were given the combination.

The findings of the study were presented at the CTRC-AACR San Antonio Breast Cancer Symposium.